These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. SARS-CoV-2 infection and thrombotic complications: a narrative review. Moschonas IC; Tselepis AD J Thromb Thrombolysis; 2021 Jul; 52(1):111-123. PubMed ID: 33449290 [TBL] [Abstract][Full Text] [Related]
4. Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature. Fattizzo B; Pasquale R; Bellani V; Barcellini W; Kulasekararaj AG Front Immunol; 2021; 12():791429. PubMed ID: 34899761 [TBL] [Abstract][Full Text] [Related]
6. A double edged-sword - The Complement System during SARS-CoV-2 infection. Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L Life Sci; 2021 May; 272():119245. PubMed ID: 33609539 [TBL] [Abstract][Full Text] [Related]
7. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Fletcher-Sandersjöö A; Bellander BM Thromb Res; 2020 Oct; 194():36-41. PubMed ID: 32569879 [TBL] [Abstract][Full Text] [Related]
8. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Merrill JT; Erkan D; Winakur J; James JA Nat Rev Rheumatol; 2020 Oct; 16(10):581-589. PubMed ID: 32733003 [TBL] [Abstract][Full Text] [Related]
12. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052 [TBL] [Abstract][Full Text] [Related]
13. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635 [TBL] [Abstract][Full Text] [Related]
14. The case of complement inhibitors. Noris M Adv Biol Regul; 2021 Aug; 81():100822. PubMed ID: 34454870 [TBL] [Abstract][Full Text] [Related]
15. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. Asif A; Nayer A; Haas CS J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226 [TBL] [Abstract][Full Text] [Related]
16. Viral Coagulopathy in Patients With COVID-19: Treatment and Care. Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449 [TBL] [Abstract][Full Text] [Related]
17. Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. Peerschke EI; Valentino A; So RJ; Shulman S; Ravinder Front Immunol; 2021; 12():716361. PubMed ID: 34491250 [TBL] [Abstract][Full Text] [Related]
18. Thrombosis in COVID-19. Hanff TC; Mohareb AM; Giri J; Cohen JB; Chirinos JA Am J Hematol; 2020 Dec; 95(12):1578-1589. PubMed ID: 32857878 [TBL] [Abstract][Full Text] [Related]
19. Complement activation and coagulopathy - an ominous duo in COVID19. Tomo S; Kumar KP; Roy D; Sankanagoudar S; Purohit P; Yadav D; Banerjee M; Sharma P; Misra S Expert Rev Hematol; 2021 Feb; 14(2):155-173. PubMed ID: 33480807 [TBL] [Abstract][Full Text] [Related]
20. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Miesbach W; Makris M Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]